High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event‐free survival
Open Access
- 2 September 2009
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 146 (6) , 669-674
Abstract
Summary: WT1 gene expression has been proposed as a useful marker of minimal residual disease in leukaemia. Its utility in paediatric haematopoietic stem cell transplantation (HSCT) has not been studied. We studied the prognostic value of WT1 expression in peripheral blood prior to HSCT in 36 children with acute myeloid leukaemia (AML). Samples were obtained 2 weeks pre‐transplant to determine the level of WT1 expression. WT1 expression was normalized using K562 cells as a control and a relative value of 0·5 was chosen as the cut‐off point between high and low WT1 expression. The median level of pre‐transplant WT1 expression in the 36 patients was 0·09 (range 0·0001–11·0), with 11patients having WT1 ≥ 0·5 and 25, WT1 < 0·5. After HSCT, 76% of patients with high pre‐transplant WT1 expression relapsed, in contrast to 0% of the patients with low WT1 expression. Those with high WT1 expression had significantly lower 5‐year event‐free survival (EFS) (18%, 95% CI 0–40%) as compared to those with low WT1 expression (68%, 95% CI 50–86%, P = 0·007). Multivariate analysis showed that pre‐transplant WT1 level is the only significant prognostic factor for the difference in EFS. Our finding suggests that elevated WT1 gene expression before HSCT in paediatric AML predicts relapse and poor long‐term EFS. A larger prospective study is warranted to compare the value of high WT1 expression and other markers of minimal residue disease in predicting clinical outcomes after HSCT.Keywords
This publication has 20 references indexed in Scilit:
- Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring and Novel Chemotherapeutic, Molecular, and Immune Approaches Aimed at Preventing RelapseTransplantation and Cellular Therapy, 2009
- Status of minimal residual disease testing in childhood haematological malignanciesBritish Journal of Haematology, 2008
- High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid LeukemiaJournal of Clinical Oncology, 2006
- Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemiaBone Marrow Transplantation, 2004
- Detection of Minimal Residual Disease in Acute Myelogenous LeukemiaActa Haematologica, 2004
- WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre studyBritish Journal of Haematology, 2004
- Utility of WT1 as a Reliable Tool for the Detection of Minimal Residual Disease in Children with LeukemiaPediatric and Developmental Pathology, 2002
- A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer GroupBlood, 2001
- wt1 Gene Expression in Childhood Acute LeukemiasActa Haematologica, 2000
- Detection of minimal residual disease in acute leukemia by flow cytometryCytometry, 1999